(Circulation. 1997;96:1291-1298.)
© 1997 American Heart Association, Inc.
Articles |
Rat Arterial Wall Retains Myointimal Hyperplastic Potential Long After Arterial Injury
From Harvard-MIT Division of Health Sciences and Technology (M.G.S., E.R.E.) and Department of Biology (D.J.K., R.D.R.), Massachusetts Institute of Technology, Cambridge, Mass, Brigham and Women's Hospital (E.R.E.) and Beth Israel Hospital Departments of Medicine (M.S., R.D.R.), Harvard Medical School, Boston, Mass.
Correspondence to Martin G. Sirois, PhD, Research Center, Room S-5450, Montreal Heart Institute, 5000 Belanger St, Montreal, Quebec, Canada.
Background Many novel molecular and pharmacological modalities have been proposed for the treatment of accelerated vascular diseases. Yet the fundamental question remains of whether the vessel wall can be treated once only or whether single-dose therapy simply delays the inevitable processes that lead to intimal hyperplasia. Since platelet adhesion and aggregation are critical events in vascular healing, we sought to determine whether the injured blood vessel would retain its myointimal potential after reversal of even prolonged periods of thrombocytopenia.
Methods and Results A novel nonimmune method sustained thrombocytopenia and suppressed postinjury neointimal hyperplasia by 88%. Infusion of fresh platelets, even 14 days after initial denuding injury, restored the full neointimal hyperplastic potential. Platelet depletion presumably removed factors chemotactic for vascular smooth muscle cells but had no effect on the overexpression of the platelet-derived growth factor receptor-ß (PDGFR-ß) subunit after vascular injury. In native vessels, 26.5±2.5% of medial smooth muscle cells expressed PDGFR-ß. In all animals, medial PDGFR-ß expression doubled 2 weeks after endothelial denudation and was evident in up to 74.5±2.5% of the cells forming the neointima.
Conclusions Thus, though the hyperplastic potential of the injured blood vessel can be delayed with removal of growth stimuli, it is not lost forever, and if the media is not made quiescent, neointimal hyperplasia is simply delayed rather than prevented. These results may have a profound effect on our understanding and treatment of accelerated proliferative vascular diseases.
Key Words: busulfan • platelet-derived factors • restenosis • cells, muscle, smooth • thrombocytopenia
This article has been cited by other articles:
 |
|
 |
|
  I. Fishbein, I. Alferiev, M. Bakay, S. J. Stachelek, P. Sobolewski, M. Lai, H. Choi, I. -W. Chen, and R. J. Levy Local Delivery of Gene Vectors From Bare-Metal Stents by Use of a Biodegradable Synthetic Complex Inhibits In-Stent Restenosis in Rat Carotid Arteries Circulation, April 22, 2008; 117(16): 2096 - 2103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawamoto, J. Aoki, A. Tanaka, A. Itakura, H. Hosono, H. Arai, Y. Kiso, and H. Matsuda Nerve Growth Factor Activates Mast Cells Through the Collaborative Interaction with Lysophosphatidylserine Expressed on the Membrane Surface of Activated Platelets J. Immunol., June 15, 2002; 168(12): 6412 - 6419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fishbein, M. Chorny, S. Banai, A. Levitzki, H. D. Danenberg, J. Gao, X. Chen, E. Moerman, I. Gati, V. Goldwasser, et al. Formulation and Delivery Mode Affect Disposition and Activity of Tyrphostin-Loaded Nanoparticles in the Rat Carotid Model Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1434 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Windecker, I. Mayer, G. De Pasquale, W. Maier, O. Dirsch, P. De Groot, Y.-P. Wu, G. Noll, B. Leskosek, B. Meier, et al. Stent Coating With Titanium-Nitride-Oxide for Reduction of Neointimal Hyperplasia Circulation, August 21, 2001; 104(8): 928 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawasaki, M. Dewerchin, H. R. Lijnen, I. Vreys, J. Vermylen, and M. F. Hoylaerts Mouse Carotid Artery Ligation Induces Platelet-Leukocyte-Dependent Luminal Fibrin, Required for Neointima Development Circ. Res., February 2, 2001; 88(2): 159 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawasaki, M. Dewerchin, H. R. Lijnen, J. Vermylen, and M. F. Hoylaerts Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice Blood, July 1, 2000; 96(1): 153 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Alt, I. Haehnel, C. Beilharz, K. Prietzel, D. Preter, A. Stemberger, T. Fliedner, W. Erhardt, and A. Schomig Inhibition of Neointima Formation After Experimental Coronary Artery Stenting : A New Biodegradable Stent Coating Releasing Hirudin and the Prostacyclin Analogue Iloprost Circulation, March 28, 2000; 101(12): 1453 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Giese, M. M. H. Marijianowski, O. McCook, A. Hancock, V. Ramakrishnan, L. J. Fretto, C. Chen, A. B. Kelly, J. A. Koziol, J. N. Wilcox, et al. The Role of Alpha and Beta Platelet-Derived Growth Factor Receptor in the Vascular Response to Injury in Nonhuman Primates Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 900 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tazawa, T. Nakane, and S. Chiba Angiotensin II Type 1 Receptor Blockade Prevents Up-Regulation of Angiotensin II Type 1A Receptors in Rat Injured Artery J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 898 - 904. [Abstract] [Full Text]
|
|